Literature DB >> 28339069

Transglutaminase 2 is upregulated in primary hepatocellular carcinoma with early recurrence as determined by proteomic profiles.

Hiromi Yamaguchi1, Kazumichi Kuroda2, Masahiko Sugitani1, Tadatoshi Takayama3, Kiyoshi Hasegawa4, Mariko Esumi1.   

Abstract

The mechanism of early recurrence of hepato-cellular carcinoma (HCC) is not well understood. To examine whether early intrahepatic metastasis of HCC can be determined by the reliable molecular characteristics of the primary HCC, we focused on early-stage tumors of primary and solitary HCC cases. Proteomic differences were investigated between two groups, 11 early (recurrence within 12 months) and 10 late (no recurrence within 48 months) HCC cases, using two-dimensional fluorescence difference gel electrophoresis. Overall, 10 upregulated and 9 downregulated proteins were identified from a total of 1623 protein spots detected in early recurrent HCC. Cluster analysis using the 19 proteins successfully divided the 21 HCC samples exactly into the two above groups. A multifunctional protein, transglutaminase 2 (TGM2), was upregulated in the early recurrence group. Immunohistochemistry revealed the frequent observation of TGM2-positive HCC cells in the early group, with a tendency of TGM2-positive staining in HCC cells adjacent to fibrous stroma. To examine whether two major TGM2-associated pathways, epithelial-mesenchymal transition (EMT) and integrin signaling, were activated in the early recurrence group of HCC, downstream molecules of TGM2 were measured. The mRNA level of EMT-related genes was highly positively correlated with TGM2 mRNA. However, E-cadherin (CDH1) mRNA and protein were not downregulated in correlation with TGM2 expression. The phosphorylation of FAK and Akt and the downregulation of PTEN were not associated with the quantity of TGM2. Therefore, TGM2 might contribute to early HCC recurrence through signaling pathways not related to EMT and integrin signaling. The proteomics of strictly classified HCCs would be useful for characterizing pro-metastatic HCC and for developing a new therapeutic target for treatment of metastasis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28339069     DOI: 10.3892/ijo.2017.3917

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  The Gαh/phospholipase C-δ1 interaction promotes autophagosome degradation by activating the Akt/mTORC1 pathway in metastatic triple-negative breast cancer.

Authors:  Hui-Yu Lin; Chia-Hao Kuei; Hsun-Hua Lee; Che-Hsuan Lin; Jing-Quan Zheng; Hui-Wen Chiu; Chi-Long Chen; Yuan-Feng Lin
Journal:  Aging (Albany NY)       Date:  2020-07-01       Impact factor: 5.682

2.  Activated hepatic stellate cells promote epithelial-to-mesenchymal transition in hepatocellular carcinoma through transglutaminase 2-induced pseudohypoxia.

Authors:  Hui Ma; Liqi Xie; Lan Zhang; Xin Yin; Hucong Jiang; Xiaoying Xie; Rongxin Chen; Haojie Lu; Zhenggang Ren
Journal:  Commun Biol       Date:  2018-10-25

3.  MicroRNA‑214 suppresses the viability, migration and invasion of human colorectal carcinoma cells via targeting transglutaminase 2.

Authors:  Huiguo Shan; Xuefeng Zhou; Chuanjun Chen
Journal:  Mol Med Rep       Date:  2019-06-03       Impact factor: 2.952

4.  Expression And Biological Interaction Network Of RHOC For Hepatic Carcinoma With Metastasis In PBMC Samples.

Authors:  Yanting Shen; Lu Bu; Rui Li; Zhenzhu Chen; Fei Tian; Qinyu Ge
Journal:  Onco Targets Ther       Date:  2019-11-05       Impact factor: 4.147

Review 5.  Review: Challenges of In Vitro CAF Modelling in Liver Cancers.

Authors:  Alba Herrero; Elisabeth Knetemann; Inge Mannaerts
Journal:  Cancers (Basel)       Date:  2021-11-24       Impact factor: 6.639

Review 6.  Proteomic Technology "Lens" for Epithelial-Mesenchymal Transition Process Identification in Oncology.

Authors:  Monica Neagu; Carolina Constantin; Marinela Bostan; Constantin Caruntu; Simona Rebeca Ignat; Sorina Dinescu; Marieta Costache
Journal:  Anal Cell Pathol (Amst)       Date:  2019-10-29       Impact factor: 2.916

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.